Fischer Medical Ventures Limited announced the outcome of its board meeting held on August 14, 2026, approving the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. On a consolidated basis, the company reported revenue from operations of Rs 8,192.00 lakhs for the current quarter, compared to Rs 2,344.47 lakhs in the corresponding quarter of the previous year and Rs 9,753.59 lakhs in the preceding quarter. The consolidated net profit for the quarter stood at Rs 379.13 lakhs, reflecting a decrease from Rs 486.01 lakhs in the same quarter last year and a recovery from a net loss of Rs 1,243.74 lakhs in the previous quarter. For the standalone segment, revenue from operations was recorded at Rs 454.23 lakhs, up from Rs 72.17 lakhs year-on-year and Rs 410.76 lakhs quarter-on-quarter, with a net loss of Rs 60.94 lakhs showing an improvement compared to a net loss of Rs 350.41 lakhs YoY and Rs 898.18 lakhs QoQ. Additionally, the board noted the resignation of independent directors Mr. Roberto M Pagdanganan and Mr. Sanjay Jayantilal Jain, approved the reconstitution of key board committees, and sanctioned the allotment of equity shares amounting to over 2.05 crore shares via convertible warrant conversions.

Fischer Medical Ventures Limited (formerly known as Fischer Chemic Limited) is primarily engaged in the healthcare, medical devices manufacturing, and diagnostic imaging sectors, operating out of the AP Medtech Zone in Visakhapatnam and its corporate office in Chennai. The company specializes in delivering advanced medical technologies, AI-enabled healthcare diagnostic tools, and therapeutic solutions.